Using transcriptomic and functional knockdown strategies in vitro and in vivo, we identify PFK1, PDK1, PGAM1, ENO1, HK2, ALDOA and ENO2 as key glycolytic enzymes essential for GBM growth and propose them as potential therapeutic targets against GBM. This evidence concerns the gene ENO2 and glioblastoma.